K2 Medical Research Expands Access to Clinical Trials in Foxboro, MA

K2 Medical Research, a dedicated clinical research organization, has officially launched its new site in Foxboro, Massachusetts, aiming to improve access to cutting-edge clinical trials for patients in the Southern New England area. The opening, celebrated today, marks a significant addition to the region's medical research landscape, particularly in neurology, psychiatry, cardiometabolic health, and general medicine.

Located in a state-of-the-art 7,000-square-foot facility, this new site features an on-site laboratory, pharmacy, and infusion suite, all designed to facilitate a wide range of clinical trials. Dr. Daniel Sacchetti, a noted neurologist and Principal Investigator, emphasized the importance of this facility in providing local patients with access to transformative clinical research opportunities. He expressed pride in establishing a center committed to advancing neuroscience and cardiometabolic health innovations.

Who’s Who at K2 Boston

The leadership team at K2 Foxboro comprises experts with extensive backgrounds in their respective fields. Dr. Sacchetti, who joined K2 in 2025, previously served as Chief of Neurology at Southcoast Health, bringing with him decades of experience in treating neurological conditions. He completed his education at prominent institutions such as Boston College, Boston University, and the University of New England College of Osteopathic Medicine, followed by rigorous training at Brown University and New York-Presbyterian Hospital.

Working alongside Dr. Sacchetti is Dr. John Stoukides, who plays a crucial role as the Principal Investigator at Rhode Island Mood and Memory. He is also involved in academia as an assistant professor at Boston University School of Medicine and The Warren Alpert Medical School of Brown University. He holds advanced degrees from respected institutions, illustrating his deep commitment to both clinical work and medical education.

Completing the leadership trifecta is William Menard, Managing Partner at K2, who brings over 25 years of experience in the fields of psychiatry and neurology. His involvement in pivotal clinical trials, such as those leading to FDA approvals for Alzheimer’s treatments, reinforces K2’s dedication to groundbreaking research.

Clinical Trials and Community Engagement

K2 Boston is currently enrolling participants in clinical trials aimed at addressing a variety of significant medical concerns, including Alzheimer’s disease, alcohol use disorder, and major depressive disorder. As part of their community outreach, the K2 team collaborates closely with local healthcare providers, clinics, assisted living facilities, and community centers. Their commitment extends to engaging in health fairs and cultural events, as well as hosting educational seminars to enhance community knowledge about medical research and health issues.

“Today marks an exciting milestone,” said Dr. Sacchetti during the opening. “We are dedicated to bridging the gap between innovative clinical research and the community, making world-class healthcare accessible to everyone.”

Sean Stanton, the CEO and Co-Founder of K2 Medical Research, echoed this sentiment, stating, “In a region known for champions, K2 is proud to join the fight against Alzheimer’s and other devastating diseases.” The organization’s focus on collaboration among physicians, researchers, and patients emphasizes its commitment to advancing medicine while ensuring the community benefits from research outcomes.

Visit K2 Boston

The new K2 Boston site aims not only to conduct groundbreaking clinical research but also to provide an enjoyable and educational experience for participants and their families. Just two miles from Patriot Place and Gillette Stadium, the facility encourages visitors to explore the vibrant Foxboro community full of dining, shopping, and entertainment opportunities.

For those interested in participating in ongoing trials or for inquiries regarding study eligibility, K2 Boston is welcoming calls at 508-408-5252 and encourages a no-cost memory screening for potential participants.

For more information about K2 Medical Research and its mission to enhance healthcare access through clinical trials, visit k2med.com. Together, they aim to drive medical advancements that improve lives and create lasting impacts on the future of healthcare.